Pošalji zapis e-poštom: PERSISTENCE OF LYMPHOCYTOTOXIC ANTIBODIES IN PATIENTS IN THE TRIAL TO REDUCE ALLOIMMUNIZATION TO PLATELETS: IMPLICATIONS FOR USING MODIFIED BLOOD PRODUCTS